Document Detail


Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
MedLine Citation:
PMID:  21410684     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Benign prostatic hyperplasia (BPH) is the major cause of lower urinary tract symptoms in men aged 50 or older. Symptoms are not normally life threatening, but often drastically affect the quality of life. The number of men seeking treatment for BPH is expected to grow in the next few years as a result of the ageing male population. Estimates of annual pharmaceutical sales of BPH therapies range from $US 3 to 10 billion, yet this market is dominated by two drug classes. Current drugs are only effective in treating mild to moderate symptoms, yet despite this, no emerging contenders appear to be on the horizon. This is remarkable given the increasing number of patients with severe symptoms who are required to undergo invasive and unpleasant surgery. This review provides a brief background on prostate function and the pathophysiology of BPH, followed by a brief description of BPH epidemiology, the burden it places on society, and the current surgical and pharmaceutical therapies. The recent literature on emerging contenders to current therapies and novel drug targets is then reviewed, focusing on drug targets which are able to relax prostatic smooth muscle in a similar way to the α(1) -adrenoceptor antagonists, as this appears to be the most effective mechanism of action. Other mechanisms which may be of benefit are also discussed. It is concluded that recent basic research has revealed a number of novel drug targets such as muscarinic receptor or P2X-purinoceptor antagonists, which have the potential to produce more effective and safer drug treatments.
Authors:
S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Related Documents :
15493534 - Auditory evoked responses in a comparison between schizophrenia patients with and witho...
23754164 - Study of osteoporosis treatment principles used historically by ancient physicians in c...
21203154 - 2-methoxy-phenyl 2-{2-[1-methyl-5-(4-methyl-benzo-yl)pyrrol-2-yl]acetamido}acetate.
7061724 - Hydrochlorothiazide pharmacokinetics and pharmacologic effect: the influence of indomet...
18500564 - In vitro studies are sometimes better than conventional human pharmacokinetic in vivo s...
287334 - Intra-arterial chemotherapy of malignant head and neck tumours with superselective angi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  British journal of pharmacology     Volume:  163     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-09     Completed Date:  2011-11-02     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  891-907     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Affiliation:
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Sab.Ventura@monash.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Discovery*
Humans
Male
Muscle Contraction / drug effects
Muscle, Smooth / drug effects
Prostatic Hyperplasia / drug therapy*,  enzymology,  metabolism*,  physiopathology
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of the contribution of I(to) to repolarization in canine ventricular myocardium.
Next Document:  Differential contributions of adenosine to hypoxia-evoked depressions of three neuronal pathways in ...